Abstract：
Oncolytic viruses (OVs) are increasingly recognized as potent tools in cancer therapy, effectively targeting and eradicating oncogenic conditions while sparing healthy cells. They enhance antitumor immunity by triggering various immune responses throughout the cancer cycle. Genetically engineered OVs swiftly destroy cancerous tissues and activate the immune system by releasing soluble antigens like danger signals and interferons. Their ability to stimulate both innate and adaptive immunity makes them particularly attractive in cancer immunotherapy. Recent advancements involve combining OVs with other immune therapies, yielding promising results. Transgenic OVs, designed to enhance immunostimulation and specifically target cancer cells, further improve immune responses. This review highlights the intrinsic mechanisms of OVs and underscores their synergistic potential with other immunotherapies. It also proposes strategies for optimizing armed OVs to bolster immunity against tumors.
摘要：
溶瘤病毒（OVs）越来越被认为是癌症治疗的有效工具。有效靶向和根除致癌条件，同时保留健康细胞。它们通过在整个癌症周期中触发各种免疫反应来增强抗肿瘤免疫力。基因工程OVs迅速破坏癌组织，并通过释放可溶性抗原如危险信号和干扰素激活免疫系统。它们刺激先天和适应性免疫的能力使它们在癌症免疫疗法中特别有吸引力。最近的进步涉及将OVs与其他免疫疗法相结合，产生有希望的结果。转基因OVs,旨在增强免疫刺激并特异性靶向癌细胞，进一步改善免疫反应。这篇综述强调了OVs的内在机制，并强调了它们与其他免疫疗法的协同潜力。它还提出了优化武装OV以增强对肿瘤的免疫力的策略。
